Verastem (VSTM) to Release Quarterly Earnings on Wednesday

Verastem (NASDAQ:VSTM) is expected to be releasing its Q4 2025 results after the market closes on Wednesday, March 4th. Analysts expect Verastem to post earnings of ($0.49) per share and revenue of $16.8510 million for the quarter. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Wednesday, March 4, 2026 at 4:30 PM ET.

Verastem Stock Up 3.5%

VSTM stock opened at $5.90 on Wednesday. The business’s 50-day moving average price is $6.82 and its 200-day moving average price is $8.30. The stock has a market cap of $394.00 million, a P/E ratio of -1.46 and a beta of 0.41. The company has a quick ratio of 2.55, a current ratio of 2.58 and a debt-to-equity ratio of 2.06. Verastem has a twelve month low of $4.01 and a twelve month high of $11.24.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on VSTM shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Verastem in a report on Wednesday, January 21st. Mizuho set a $18.00 target price on shares of Verastem in a research note on Thursday, February 19th. Cantor Fitzgerald raised shares of Verastem to a “strong-buy” rating in a report on Thursday, October 30th. Zacks Research cut Verastem from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 18th. Finally, Guggenheim restated a “buy” rating on shares of Verastem in a research report on Tuesday, December 30th. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Verastem has a consensus rating of “Moderate Buy” and an average target price of $16.33.

Insider Activity at Verastem

In related news, CEO Dan Paterson sold 10,321 shares of the business’s stock in a transaction on Monday, January 12th. The shares were sold at an average price of $7.16, for a total value of $73,898.36. Following the sale, the chief executive officer owned 400,104 shares in the company, valued at approximately $2,864,744.64. The trade was a 2.51% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Daniel Calkins sold 5,039 shares of the company’s stock in a transaction on Monday, January 12th. The shares were sold at an average price of $7.16, for a total transaction of $36,079.24. Following the sale, the chief financial officer directly owned 104,719 shares in the company, valued at approximately $749,788.04. The trade was a 4.59% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 29,678 shares of company stock worth $253,405 over the last ninety days. Insiders own 2.10% of the company’s stock.

Hedge Funds Weigh In On Verastem

A number of institutional investors and hedge funds have recently made changes to their positions in VSTM. RTW Investments LP raised its position in shares of Verastem by 21.2% during the 4th quarter. RTW Investments LP now owns 6,576,306 shares of the biopharmaceutical company’s stock valued at $50,769,000 after buying an additional 1,150,000 shares in the last quarter. Polar Capital Holdings Plc grew its position in Verastem by 270.7% in the fourth quarter. Polar Capital Holdings Plc now owns 3,925,126 shares of the biopharmaceutical company’s stock worth $30,302,000 after acquiring an additional 2,866,350 shares in the last quarter. Vanguard Group Inc. increased its stake in Verastem by 1.6% during the third quarter. Vanguard Group Inc. now owns 3,479,011 shares of the biopharmaceutical company’s stock worth $30,720,000 after acquiring an additional 55,394 shares during the last quarter. State Street Corp raised its position in Verastem by 44.5% during the fourth quarter. State Street Corp now owns 3,219,295 shares of the biopharmaceutical company’s stock valued at $24,853,000 after purchasing an additional 990,655 shares during the period. Finally, Nantahala Capital Management LLC raised its position in Verastem by 28.5% during the second quarter. Nantahala Capital Management LLC now owns 2,954,735 shares of the biopharmaceutical company’s stock valued at $12,262,000 after purchasing an additional 656,194 shares during the period. 88.37% of the stock is owned by hedge funds and other institutional investors.

Verastem Company Profile

Verastem Oncology, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapies that target cancer stemness and resistance pathways. Established in 2010 and headquartered in Needham, Massachusetts, Verastem Oncology applies a precision-medicine approach to identify key signaling nodes responsible for tumor growth and relapse, with an emphasis on hematologic malignancies and solid tumors. The company’s research platform integrates insights into complex signaling networks to advance novel compounds from early discovery through clinical proof of concept.

The company’s lead marketed product is COPIKTRA (duvelisib), an oral inhibitor of PI3K-delta and PI3K-gamma, which received U.S.